Recent News

• 11.21.2025 - Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
• 11.21.2025 - Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
• 11.21.2025 - Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
• 11.20.2025 - Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
• 11.20.2025 - Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
• 11.20.2025 - Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
• 11.20.2025 - Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
• 11.20.2025 - Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
• 11.20.2025 - Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
• 11.14.2025 - Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

Recent Filings

• 11.14.2025 - EX-99.1 EX-99.1
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.14.2025 - 8-K Current report
• 08.28.2025 - 3/A Initial statement of beneficial ownership of securities
• 08.28.2025 - 3/A Initial statement of beneficial ownership of securities
• 08.28.2025 - 4 Statement of changes in beneficial ownership of securities